In collaboration with eminent multidisciplinary clinicians and scientists in the field of pancreatic cancer from Germany, Japan, and the United States, Cancer Cancer Amsterdam researchers prof. dr. Marc Besselink (surgeon), prof. dr. Hanneke Wilmink (medical oncologist), and drs. Thomas Stoop (PhD candidate) published this review on pancreatic cancer in The Lancet.
Pancreatic cancer is a highly lethal disease due to its aggressive tumor biology and non-specific symptoms (Figure 1), associated with a median survival of only 4 months with a five-year overall survival of only 13%. This complex disease requires a multidisciplinary approach, provided by expert centers. As pancreatic cancer will become the second leading cause of cancer-related death by 2030, there is an urgent need for novel tumor-targeted therapies.
This review provides guidance for students, general practitioners, scientists, and both academic and non-academic clinicians in the developing field of this complex and highly challenging disease.
Figure 1. Symptoms of pancreatic cancer
Most common symptoms and signs of pancreatic cancer at diagnosis. These symptoms are more often seen in patients with pancreatic cancer located in the pancreatic body or tail compared with pancreatic head tumours.
† These symptoms are more often seen in patients with pancreatic cancer located in the pancreatic head compared with pancreatic body or tail tumours.
Link to the publication: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00261-2/abstract
Involved researchers
- Thomas F. Stoop(CCA)
- Ammar A. Javed
- Atsushi Oba
- Bas Groot Koerkamp
- Thomas Seufferlein
- Johanna W. Wilmink (CCA)
- Marc G. Besselink (CCA)
Funding
None